Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare two types of targeted radiation therapy for men with recurrent prostate ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment. A new Phase 2 clinical trial at UC Davis Comprehensive Cancer Center unveiled clues as to why these ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver ...

Early-stage trials of a new drug for advanced prostate cancer have yielded "remarkable" results, according to medical experts. This innovative treatment, an immunotherapy designed to harness the ...

Current guidelines for clinically localized prostate cancer offer a wide range of management options, from active surveillance to surgery and radiation therapy (RT). Treatment selection depends on ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one agent shown to shrink tumors in patients whose disease had resisted every ...

MRI reports and biopsy pathology reports were extracted from a cohort of 1,360,866 patients with PCa in the VA Cancer Registry System or the VA Corporate Data Warehouse, with 155,570 patients having ...

The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver ...